))
Early-Stage Non–Small Cell Lung Cancer: Answers to Frequently Asked Questions
Manage episode 423438379 series 3456244
A tartalmat a i3 Health and I3 Health biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a i3 Health and I3 Health vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.
In this video, Dr. Jamie E. Chaft, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, answers questions asked by the audience during her CME/NCPD–approved activity with i3 Health, Leveraging the Growing Arsenal of Therapies for Early-Stage Non–Small Cell Lung Cancer (NSCLC), chaired by Dr. Helena Yu. Dr. Chaft shares insights into emerging roles of measurable residual disease (MRD) in lung cancer, the significance of the recent approval of alectinib for ALK-positive disease, treatment considerations for older versus younger patients, important research updates at the American Society of Clinical Oncology (ASCO) Annual Meeting, and more! Interested in completing this activity and earning FREE CME/NCPD credit? Click here: https://bit.ly/4b3QDXJ
…
continue reading
50 epizódok
Megosztás
